| Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. | |
| | |
MedLine Citation:
|
PMID: 18757264 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Tumor marker cancer antigen (CA) 27.29 and combined [18F]-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans are used to follow up response to treatment and disease progression in patients with metastatic breast cancer (MBC). Recently, circulating tumor cell testing (CTC) has been used in this context. It is not known if 1 of the 3 tests can be a surrogate for another. PATIENTS AND METHODS: We analyzed a database of 35 patients with MBC. There were 173 time points (> or = 6 weeks apart) when > or = 2 of these tests were performed. Correlation among all the 3 tests was statistically analyzed. RESULTS: Results of PET/CT scans were compared with CA 27.29 at 163 time points. There was a statistically significant correlation between both groups (P = .02); however, sensitivity of CA 27.29 to detect metastatic disease observed on PET/CT scan was 59%. The results of PET/CT scans were compared with CTC at 93 events, where there was a statistically significant correlation between both groups (P = .0002); however, sensitivity of CTC to detect metastatic disease shown on PET/CT scans was 55%. Cancer antigen 27.29 results were also compared to CTC at 100 events, where there was a statistically significant correlation between both groups (P = .0002). However, only 64% of patients with high CA 27.29 had abnormal CTC. CONCLUSION: Our data shows correlation among PET/CT scan, CA 27.29, and CTC. However, both CA 27.29 and CTC had poor sensitivity and negative predictive value to detect metastatic disease observed on PET/CT scan. Normal CA 27.29 testing or CTC has to be interpreted cautiously in patients with MBC. |
| | |
Authors:
|
Ayman Saad; Abraham Kanate; Aasim Sehbai; Gary Marano; Gerry Hobbs; Jame Abraham |
Related Documents
:
|
18043094 - 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnos... 9406694 - Perspectives on oncologic imaging with radiolabeled antibodies. 15530804 - Combined use of mri and pet to monitor response and assess residual disease for locally... 10707924 - Values and limitations of 18f-fluorodeoxyglucose-positron-emission tomography with preo... 18043094 - 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnos... 2080354 - Use of relocatable stereotactic frame to integrate positron emission tomography and com... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Clinical breast cancer Volume: 8 ISSN: 1526-8209 ISO Abbreviation: Clin. Breast Cancer Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-09-01 Completed Date: 2008-10-14 Revised Date: 2008-12-01 |
Medline Journal Info:
|
Nlm Unique ID: 100898731 Medline TA: Clin Breast Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 357-61 Citation Subset: IM |
Affiliation:
|
Neoplastic Diseases and Related Disorders, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Antigens, Tumor-Associated, Carbohydrate / blood* Breast Neoplasms / blood, diagnosis*, pathology* Female Fluorodeoxyglucose F18 / diagnostic use* Humans Middle Aged Neoplastic Cells, Circulating* Positron-Emission Tomography* Retrospective Studies Sensitivity and Specificity Tomography, X-Ray Computed* Tumor Markers, Biological / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, Tumor-Associated, Carbohydrate; 0/CA 27-29 antigen; 0/Tumor Markers, Biological; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
Erratum In:
|
Clin Breast Cancer. 2008 Oct;8(5):457 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lymphopenia associated with adjuvant anthracycline/ taxane regimens.
Next Document: Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.